Investors Encouraged to Pursue Claims Against ATyr Pharma After Significant Losses

Investor Alert: Claims Encouraged for Affected ATyr Investors

Recent developments concerning ATyr Pharma, Inc. have raised substantial concerns among investors who have endured significant losses. Faruqi & Faruqi, LLP, a preeminent player in securities law, is alerting investors that they may be eligible to pursue legal action. If you have suffered losses exceeding $50,000 in ATyr within the timeframe of January 16, 2025, to September 12, 2025, you are encouraged to reach out to the firm to explore your legal rights and options.

Allegations Against ATyr Pharma

The firm has initiated an investigation into ATyr Pharma (NASDAQ: ATYR) regarding potential securities violations. The allegations suggest that ATyr's executives may have made misleading statements about the effectiveness of their product, efzofitimod, leading to a misrepresentation of its capabilities. Specifically, the complaint asserts that while executives provided overly optimistic statements about the drug's ability to facilitate complete tapering off steroids, they failed to disclose critical adverse information that negatively impacted investors.

In clinical trials, particularly the EFZO-FIT study, efzofitimod did not demonstrate significant improvement in reducing mean daily oral corticosteroid (OCS) doses when compared to a placebo. This critical failure has caused a sharp decline in stock value, which plummeted by 83.25% following the public release of study results. Moreover, the data indicated that only about 52.6% of patients could completely taper off steroids compared to 40.2% with a placebo. This stark discrepancy raised red flags about the company's prior communications regarding the drug's efficacy.

What Investors Should Do

Investors who feel affected by the decline in ATyr's stock and the alleged misinformation are encouraged to act promptly. The deadline for filing as lead plaintiff in a federal securities class action against ATyr is approaching on December 8, 2025. Participating as a lead plaintiff provides individuals with the unique opportunity to not only protect their interests but also to lead the case on behalf of other affected investors. However, any member of the potential class can still choose to remain a passive member without being involved in the leadership role. The decision around this is entirely personal and should be made based on one's situation.

Faruqi & Faruqi's track record speaks for itself, having successfully recovered hundreds of millions of dollars for investors since its establishment in 1995. The firm is advocating for those who may have insights into ATyr’s practices, including former employees, whistleblowers, and shareholders, to come forward.

Contact Information

If you or someone you know is interested in discussing potential claims against ATyr Pharma, please do not hesitate to contact attorney James (Josh) Wilson at Faruqi & Faruqi. You can reach him at 877-247-4292 or 212-983-9330 (Ext. 1310) for a confidential consultation.

For further details regarding the class action initiative or to stay updated, please visit Faruqi & Faruqi’s website.

This alert serves as a call to action for investors who have suffered losses as a result of alleged securities violations by ATyr and is a reminder of the importance of supporting and advocating for your rights as a shareholder.